KYNTRA BIO, INC. 8-K

What Happened
Kyntra Bio, Inc. (filed Form 8‑K, Item 3.01, on April 9, 2026) announced it received a letter from Nasdaq on April 2, 2026 notifying the company that it does not meet the Nasdaq Global Select Market continued listing requirement under Listing Rule 5450(b)(3)(A) for $50 million in total assets and total revenue for the most recently completed fiscal year (or two of the last three). Nasdaq cited that revenue from FibroGen International was presented as held for sale (discontinued operations) in 2024 and 2025, which contributed to the non‑compliance. The notice has no immediate effect on the trading of Kyntra Bio’s common stock.

Key Details

• Date of Nasdaq notice: April 2, 2026; Form 8‑K filed April 9, 2026 (Item 3.01).
• Rule cited: Nasdaq Listing Rule 5450(b)(3)(A) (the $50 million total assets and revenue standard).
• Cause: FibroGen International revenue presented as held for sale (discontinued operations) in 2024 and 2025.
• Deadlines and options: Kyntra Bio has 45 days (by May 18, 2026) to submit a compliance plan; if Nasdaq accepts the plan it may grant up to 180 days (until September 29, 2026) to evidence compliance. The company may also consider applying to transfer to the Nasdaq Capital Market. Nasdaq will evaluate the plan based on likelihood of achieving compliance, past history, financial condition and disclosures.

Why It Matters
This notice signals potential listing risk: if Kyntra Bio does not submit an acceptable plan or subsequently fails to demonstrate compliance within Nasdaq’s review periods, Nasdaq could initiate delisting procedures. There is no immediate trading impact, but investors should watch for the company’s submitted plan, any corrective actions (e.g., financial transactions or status changes), and further Nasdaq communications that could affect the stock’s listing status, liquidity, and investor confidence.